Intravenous ondansetron induced hypersensitivity reaction: a case report

S. Nitya, M. Shanthi*, R. Meenakshi, S. Kiruthika

Department of Pharmacology, Sri Manakula Vinayagar Medical College and Hospital, Pondicherry, India

Received: 15 March 2021
Accepted: 12 April 2021

*Correspondence:
Dr. M. Shanthi,
Email: shanthibabu24@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Ondansetron a selective 5-HT\textsubscript{3} receptor antagonist has been widely used as a prophylactic antiemetic for chemotherapy induced and anaesthesia related nausea and vomiting. Anaphylaxis and anaphylactoid reaction rarely occur in less than 1% of the patients and may lead to potentially life-threatening events. This study is one such rare case report of hypersensitivity reaction to intravenous ondansetron in a perioperative setting. Familiarity about anaphylactoid reactions to intravenous ondansetron among the health practitioners would help them to bring about a rational approach to decrease its incidence.

Keywords: Ondansetron, Adverse drug reaction, Intravenous, Hypersensitivity

INTRODUCTION

Ondansetron a selective 5-hydroxytryptamine-3 (5-HT\textsubscript{3}) receptor antagonist has been widely used as a prophylactic antiemetic for chemotherapy induced and anaesthesia related nausea and vomiting.\textsuperscript{1} The most common adverse effects seen with use of ondansetron are headache, fatigue, malaise and constipation.\textsuperscript{2} Anaphylaxis and anaphylactoid reaction rarely occur in less than 1\% of the patients. This study is one such rare case report of hypersensitivity reaction to intravenous ondansetron.

CASE REPORT

A 30 year old female patient diagnosed with retained products of conception following medical termination of pregnancy done one week earlier and was posted for dilatation and curettage under anaesthesia. Patient was administered with a single intravenous injection of ondansetron 4 mg following which maculopapular rash was observed near the intravenous cannula site on the left forearm. Immediate intravenous dexamethasone 4 mg and chlorpheniramine maleate 20 mg were given after which the rash subsided within minutes. The patient had no history of similar reaction in the past to ondansetron. The adverse drug reaction was moderate in nature given by the severity assessment using Hartwig's severity assessment. Further, Naranjo's algorithm suggested a probable casualty (total score=6).

Figure 1: Intravenous administration of ondansetron.
DISCUSSION

Anaphylactoid reactions involve non IgE mediated histamine release or by activation of complement system. It produces symptoms and signs similar to that of anaphylaxis. Incidence of anaphylactoid reactions are seen with colloids, iodinated contrast agents, drugs such as neuromuscular blockers, antibiotics and opioids.1 Ondansetron is listed under the WHO essential drugs for its safe and effective antiemetic property and is being widely used for chemotherapy and anaesthesia related nausea and vomiting. Frequently reported side effects are constipation, dizziness and headache and certain cardiac arrhythmias.2 However, anaphylactoid reactions with antiemetics especially with ondansetron have been reported, albeit rarely, with the most common presentation being cutaneous rashes.3,4 Both IgE-mediated and non-IgE-mediated hypersensitivity reaction can occur with ondansetron. However, nonimmunologic induction of maculopapular rash can also occur by direct mast-cell degranulation without IgE-mediated chain reaction.5 Clinicians must be aware of such potential adverse events.

CONCLUSION

Anaphylactoid reactions during the perioperative period are often rare and may also be life-threatening. However, there is paucity in the reporting of these reactions. Familiarity about anaphylactoid reactions to intravenous ondansetron among the health practitioners would help them to bring about a rational approach to decrease its incidence.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
